Background. The US Centers for Disease Control and Prevention and the U.S. Preventive Services Task Force recommend onetime hepatitis C virus (HCV) testing for persons born and targeted testing for high-risk persons. This strategy targets HCV testing to a prevalent population at high risk for HCV morbidity and mortality, but does not include younger populations with high incidence. To address this gap and improve access to HCV testing, age-based strategies should be considered.
testing for adults aged ≥18 years (≥18 strategy). All strategies assumed targeted testing of people who inject drugs (PWID). We chose to compete these strategies because age-based strategies may enhance national implementation [10] and because the effectiveness and costs of early screening are unknown.
We simulated outcomes including HCV cases identified, linked to care, initiated treatment, and cured over a lifetime; fibrosis stage at diagnosis; liver-attributable mortality; and quality-adjusted life years (QALYs). We projected lifetime medical costs assuming a healthcare system perspective and a 3% discount rate to both costs and benefits [11] .
We used standard methods to calculate the incremental cost-effectiveness ratio (ICER) of each testing strategy as the additional cost per person for the total population divided by the QALYs gained compared to the next less expensive strategy [11] . We assumed a willingness-to-pay (WTP) threshold of $100 000/QALY [11] .
We used data from national databases, clinical trials, and observational cohorts to inform parameter values (Table 1) . We repeated the analysis under the following alternative scenarios: inefficient testing, in which identifying the same number of cases as were identified in the base case requires twice as much testing among uninfected persons, and payer restrictions on HCV treatment such that individuals must have at least Meta-analysis of Histological Data in Viral Hepatitis (METAVIR) stage F2 fibrosis and ≥6 months of sobriety prior to being treated. With regard to the inefficient testing strategy, an argument against recommending routine testing is that such an approach generally requires a greater number of persons tested to find 1 infected person. Since our base case testing rates assumed targeting that improves yield, we varied assumptions about the efficiency of such targeting to reflect the possibility of lower yield with broader testing strategies. Second, payer restrictions continue to exist in most states; therefore, it is important to explore these real-world scenarios. We conducted 1-way deterministic sensitivity analyses on the base case.
Hepatitis C Cost-Effectiveness Model Structure and Inputs

Model Structure
The model is a closed cohort microsimulation, meaning that there are no new entrants to the simulation. It simulates the lifetime course of a hypothetical cohort that has the same demographics and HCV epidemiology of the US population (see Supplementary Appendix) [12] . The model includes several modules, which are described below.
HCV Infection, Risk Factors, and Natural History
HCV prevalence is stratified by age, sex, and risk behaviors. We simulated initiation, duration, and cessation of IDU behavior. Incidence of HCV, mortality from non-HCV causes, healthcare costs, and quality of life (QoL) depend on current drug use status (Supplementary Appendix). There is an incidence of new infections among simulated people that is conditional on current IDU. In the model, this corresponds to higher HCV incidence among young people due to higher prevalence of IDU in that group and the tendency for individuals to leave IDU as they age.
As individuals advance through METAVIR stages of fibrosis, QoL decreases and healthcare costs increase. Liver-attributable mortality occurs only among individuals who have reached METAVIR stage F4 (cirrhosis). Individuals with decompensated cirrhosis face a higher mortality probability than those with compensated cirrhosis, which reflects real-world findings [13] .
HCV Testing
Individuals have a monthly probability of HCV testing that varies by age, sex, and drug use status. We modeled the effect of a recommendation for routine HCV testing as an increase in the monthly probability that a person in a group is tested. Recommending routine 1-time testing does not ensure that all receive an HCV test nor does it prevent some individuals from being tested multiple times in a lifetime.
HCV Treatment
When an individual is identified as HCV infected, that individual is first linked to HCV care, with a probability according to age. Individuals who do not link to care upon diagnosis may do so in the future (Supplementary Appendix). After successful linkage, individuals have a probability of accepting and completing HCV treatment.
HCV cure halts fibrosis progression [14, 15] , HCV-attributable costs decrease by 50% of the individual's disease stage-specific cost before therapy [16] , and HCV-related health utility reverts to that for the previous untreated stage. Finally, following cure, liver-related mortality among cirrhotic individuals is reduced by 94% [17] . Residual risk of liver death reflects ongoing risk of decompensation or hepatocellular carcinoma (HCC) [13] .
Costs
During each month, persons accrue age-and sex-stratified "background costs" attributable to non-HCV-related healthcare [18] , HCV-specific costs that vary by disease state [16] , and IDU in PWID [19] .
Utilities
"Background" utility, a function of age and unrelated to HCV, was derived from the Medical Expenditure Panel Survey (MEPS) [20. It is multiplied by HCV-specific utility [21, 22] , IDUrelated utility, and, when applicable, temporary disutility from treatment-ending major toxicity events (see Supplementary Appendix).
Model Data
HCV Infection, Risk Factors, and Natural History
Using published literature, we estimated age-and sex-stratified HCV prevalence among active PWID. Prevalence for other risk behavior groups was derived from the National Health and Nutrition Examination Survey (see Supplementary Appendix).
We modeled movement between IDU states over the course of the simulation using AIDS Linked to the Intravenous Experience (ALIVE) cohort data (see Supplementary Appendix).
HCV Testing
We estimated HCV testing rates among active PWID using data from cohorts of PWID [23] and assigned a constant testing rate to all active PWID in the simulation. We estimated testing rates and the effect of recommendation changes in the nondrug-using cohort using the MarketScan claims database (see Supplementary Appendix) [24] .
HCV Treatment
We modeled an oral, pan-genotypic HCV regimen for all genotypes and fibrosis stages [25] . In the base case, there were no treatment restrictions. Duration and treatment outcomes were derived from cohort studies and clinical trials [25, 26] . Individuals identified as HCV infected for the first time have a probability of linking to care (ie, "linkage"). If such individuals do not link to care at that time, they may be identified with subsequent testing. Therefore, they have a probability of linking to care with each subsequent identification. The "relink" parameter refers to this subsequent linkage probability. We assessed costs from the healthcare system perspective in 2016 US dollars. We derived costs from the 2016 laboratory and physician fee schedules from the Centers for Medicare and Medicaid Services for reimbursement [27, 28] . HCV treatment costs were derived by using the average wholesale price minus 23%. We explored HCV-attributable costs in sensitivity analysis (Supplementary Tables 4 and 5 ).
Utilities
We used a combination of MEPS data and published health utility literature estimates to derive health state-related utilities [18, 21, 29] .
Monte Carlo Variance Reduction
We developed a strategy that enabled us to improve the precision of estimates since results would otherwise be subject to substantial Monte Carlo error (Supplementary Appendix). Briefly, we simulated a large cohort and noted infection status over time for each individual. For those individuals who never became infected, we recorded key health and economic outcomes and did not resimulate their life courses under each of the comparator strategies in the analysis. We deterministically calculated life expectancy and healthcare costs for this subgroup. For those who were infected, we simulated life courses following infection under each of the various screening strategies to determine health outcomes, life expectancy, and costs. For all cost and health outcomes used in the cost-effectiveness calculations, we computed population-weighted averages that combined outcomes among the never-infected group and the infected group.
Study Approval
This secondary analysis of published literature and deidentified data sources did not require institutional review board approval.
RESULTS
In the SOC strategy, 71% of all HCV-infected persons were identified and 44% of HCV-infected persons were cured over a lifetime (Figure 1) . The proportion of individuals in the total US population diagnosed prior to cirrhosis was 58%, and 32% of those who were HCV infected ultimately died from liver disease (data not shown). Among HCV-infected persons born outside the birth cohort, 67% of cases were diagnosed prior to developing cirrhosis, and liver-related mortality among HCVinfected persons was 27% (Table 2) .
Clinical Outcomes
Expanded age-based testing strategies increased lifetime case identification and cure rates in the US population, with the greatest increases observed in the ≥18 strategy (Figure 1 ). Compared to the SOC, the ≥18 strategy resulted in an estimated 256 000 additional infected persons identified, 280 000 additional cures, and an estimated 4400 fewer cases of HCC in the United States (assuming an HCC incidence rate of 2.49 per 100 person-years with cirrhosis) [30] over the lifetime of this cohort. The average number of lifetime tests increased Table 2 and Supplementary Figure 1) . Clinical outcomes over different time horizons are included in the Supplementary Appendix ( Supplementary Figures 2 and 3) .
Among the HCV-infected population born outside of the birth cohort, case detection rates increased from 74% to 85% and cure rates increased from 49% to 61%, which resulted in a 31% reduction in the proportion reaching cirrhosis before diagnosis and a 21% reduction in liver-attributable mortality in the ≥18 strategy compared to the SOC ( Table 2) .
The ≥18 strategy resulted in an increase in life expectancy from 67.2 to 68.2 years compared to the SOC in this population (Table 2 ) and 1 discounted quality-adjusted life day across the general population (Table 3) .
Cost Outcomes
As testing began at younger ages, HCV-related costs comprised a smaller portion of the incremental cost of each strategy compared to the next most inclusive (Figure 2 ). All strategies resulted in decreased costs related to managing chronic HCV and advanced liver disease including HCC. The cost of HCV testing in the SOC strategy corresponds to approximately $2500 per case diagnosed. In the ≥18 strategy, the cost of testing increased to $4400 per case diagnosed. The additional cost of testing per case diagnosed was $1900.
Incremental Cost-Effectiveness Ratio
In the base case, the ≥18 strategy provided the greatest quality-adjusted life expectancy and the lowest cost/QALY gained. This strategy dominated all other expanded testing strategies by extended dominance with an ICER compared to the SOC of $28 000/QALY (Table 3) .
Scenario Analysis
In the inefficient testing scenario that required twice as much testing among uninfected persons to identify the same cases, the average discounted cost of the ≥18 strategy increased minimally to $126 170 (from $126 150 in the base case). That strategy remained cost-effective, with an ICER compared to ≥30 strategy of $44 000. In the treatment restriction scenario, the ≥18 strategy ICER remained cost effective but increased to $34 000/QALY (Supplementary Tables 22 and 23 ).
Sensitivity Analysis
In 1-way sensitivity analyses, the ≥18 strategy had an ICER <$100 000/QALY compared to its next best alternative across broad parameter ranges (Supplementary Tables 4-21) , except for the scenario when an individual could only link to care when first identified as infected and never again (Supplementary Table 20 ). In other scenarios, specifically, when there was no improvement in QoL and costs decreased following early-stage cure, when cost of early-stage disease was $0, and when treatment costs were varied, the ≥30 strategy dominated the ≥40 strategy by extended dominance, but the ≥18 strategy remained cost-effective (Supplementary Tables 6, 12-13, 21) . We note that the ≥18 strategy remained cost-effective, with an ICER of $30 000 when there was no mortality benefit from sustained virologic response (SVR; Supplementary Table 8) .
DISCUSSION
We used a simulation model of HCV to investigate the clinical outcomes, costs, and cost-effectiveness of age-based strategies for routine HCV testing that could replace current cohort-based guidance in the United States. We found that a recommendation for 1-time testing of all adults, with continued risk-based testing throughout life, improved clinical outcomes and was cost-effective in the United States.
The birth cohort recommendation focuses the testing effort among the group that has had the highest HCV prevalence [31] . The HCV epidemic is changing, with an increasing proportion of persons with HCV outside of this cohort. The shift is multifactorial, including premature mortality in the birth cohort [32] , persons in the birth cohort treated and cured of their infection [33] , and higher incidence of new HCV infections among younger PWID [6] . A substantial number of undiagnosed cases Abbreviations: HCV, hepatitis C virus; LY, life years; QALY, quality-adjusted life years. a Additional details of the sensitivity analyses as well as the inefficient testing and payer restriction alternative scenarios are provided in the Supplementary Appendix.
b Values that appear the same differed beyond the third decimal place exist outside of the birth cohort and might never be diagnosed under the current strategy [8] . Expansion of the recommendation for routine testing to include all adults would increase the probability of testing and identify more people with HCV.
Other analyses have demonstrated that HCV testing is cost-effective in high-prevalence settings such as among baby boomers [7] , in substance use disorder treatment programs [34] , and in prisons and jails [35] , as well as in subpopulations that include adolescents and young adults [36] and human immunodeficiency virus-infected men who have sex with men [37] . Our study takes the next step in this evolution of thought and policy about HCV testing to consider routine HCV testing for all adults.
The value of screening all adults lies in the value of early diagnosis. In our base case, routine testing of adults aged ≥18 years dominated the other age-based strategies by extended dominance. The ≥18 strategy identifies cases sooner than the other strategies, thereby increasing QoL and decreasing costs associated with HCV, since there is disutility and cost for the years that a person lives with HCV, even with early-stage disease. When we assume no QoL improvement or cost decrease associated with treating early-stage HCV, the ≥18 strategy no longer The overall incremental cost-effectiveness ratio was calculated as the difference in the average discounted costs for the total US population divided the difference in the discounted quality-adjusted life expectancy for the total US population, all discounted at 3% per year. c Values that appear the same differed beyond the third decimal place.
d Dominated = extended dominance means that the strategy was more costly and more effective but had a lower incremental cost-effectiveness ratio compared to other strategies.
Figure 2.
Incremental healthcare use costs by strategy over the lifetime. The bar graph illustrates the incremental costs relative to the previous strategy by type of healthcare expenditure for each testing strategy. The first grouping of bars is the incremental costs of 1-time testing for adults aged ≥40 years (≥40 strategy) compared to the standard of care (1-time testing for all persons born between 1945 and 1965). Next are incremental costs for 1-time testing for adults aged ≥30 years (≥30 strategy) compared to the costs for the ≥40 strategy followed by the incremental costs of the 1-time testing for adults aged ≥18 years compared to costs for the ≥30 strategy. In all 3 strategies, hepatitis C virus (HCV) testing, HCV therapy, and other non-HCV healthcare are costs (positive value) that outweighed the cost savings from HCV management (negative value). Non-HCV healthcare costs become a larger proportion of the overall incremental costs in younger testing strategies. Abbreviation: HCV, hepatitis C virus.
dominates the ≥30 strategy but does prevent enough liver-attributable morbidity and mortality to remain cost-effective. Ultimately, the cost-effectiveness of expanding testing to ≥18 is driven by reductions in cirrhosis and liver-related mortality, including HCC, while the reason it dominates other strategies is driven by QoL improvements and cost reductions associated with treating early-stage HCV. New recommendations should continue to include targeted testing among PWID, which effectively serves as a "backstop" to catch later incident cases missed by the ≥18 strategy. Findings from our alternative scenarios deserve discussion. First, while an argument against routine testing is that it is a resource-intensive effort to find a small number of cases, our findings demonstrate that routine testing was cost-effective even when we tested twice as much to find the same number of cases. Second, though testing in our treatment restriction scenario was cost-effective, this conclusion is not an endorsement of these restrictive policies. Rather, this scenario recognizes the status quo in many states and demonstrates that even if patients are treated only once they reach advanced fibrosis, it remains cost-effective to test all adults.
There were limitations to our study. First, the use of cohort studies and large national databases to derive estimates may not be representative of the overall US population; however, our detailed analysis of testing rates in MarketScan [24] are in line with previously published reports [38] [39] [40] . Second, there is relatively little evidence on the cost of early-stage HCV and the magnitude of the change in health-related utilities derived from treating early-stage HCV. Our sensitivity analyses demonstrated that earlier testing remained cost-effective even in the setting in which treating early-stage disease had no implications for cost or QoL. Third, differences between strategies are small and could be suspected to reflect Monte Carlo variance. We anticipated this because the life expectancy change in the general population attributable to expanded HCV testing is expected to be small, even at a high general population prevalence of 3%, because the majority remain uninfected and get no benefit from testing. We minimized Monte Carlo error in our results with a variance reduction strategy outlined in the Methods section and in the Supplementary Appendix. We empirically assessed the degree of variance between runs to ensure that the difference between strategies expected from random variance is smaller than the difference in outcomes seen between strategies ( Supplementary  Figures 4-12) . Fourth, we used a closed cohort but allowed individuals who were aged <18 years into guidance. Using a closed cohort in this way will be biased by omitting some future consequences of different screening strategies. Because the omitted consequences will occur 2 decades or more into the future, the impact of the omission will be relatively small compared to the overall magnitude of the population-level cumulative outcomes, especially given uncertainties about long-term changes in demography and HCV epidemiology and in the presence of a positive discount rate, as in our main analyses. Fifth, the rate of fibrosis progression with HCV is uncertain. We used one appropriate estimate of fibrosis progression rates and performed sensitivity analyses to ensure that such uncertainty did not have a major impact on the qualitative conclusions. Finally, while we did not incorporate incident infection explicitly related to factors such as tattoos, HCV incidence in the United States due to these risk factors is small in comparison to IDU [6] . We explored the impact of nondrug use-related HCV on cost-effectiveness conclusions, and our results remained robust.
In conclusion, in addition to risk-based testing, routine, 1-time HCV testing of persons aged ≥18 years is cost-effective, could lead to improved clinical outcomes, and is likely to identify more persons with HCV than the current birth cohort recommendations. These findings should be considered for future recommendation revisions.
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